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Abstract
Maintaining the redox balance within the mitochondria is critical for cellular homeostasis in the eye since the mitochondria 
host the energy producing systems of  the cell and it is widely recognized that damage to the mitochondria plays a key role in 
sight threatening age-related eye disorders, including retinopathies (maculodystrophy, retinitis pigmentosa , hereditary optic 
neuropathy), as well as glaucoma, cataract, and autoimmune uveitis. 
Reactive oxygen species (ROS) are generated as by-products of  cellular metabolism, primarily in the mitochondria. Al-
though ROS are essential participants in cell signaling and regulation, when their cellular production overwhelms the intrin-
sic antioxidant capacity, damage to cellular macromolecules such as DNA, proteins, and lipids ensues.
Oxidized phospholipids play an important role in execution of  the mitochondrial stage of  apoptosis and clearance of  ap-
optotic cells. During the lipid peroxidation (LPO) reaction, lipid hydroperoxides are formed as primary products. Several 
lines of  evidence suggest that lipid hydroperoxides can trigger cell death in many cell types, which may be mediated by mi-
tochondria dysfunction pathway. Recently, there was a breakthrough in mitochondrial targeting of  antioxidants. Mitochon-
drial function can be manipulated selectively by targeting bioactive compounds to mitochondria in living cells. Lipophylic 
antioxidants were covalently coupled to a triphenylphosphonium cation, and these compounds were preferentially taken up 
by mitochondria.
In this work we proposed the combined use of  mitochondria-targeted antioxidant mito Vit E and N-acetylcarnosine, an 
ophthalmic prodrug of  L-carnosine in patented formulation of  eye drops including the mucoadhesive compound car-
boxymethylcellulose to help elucidate the role of  mitochondrial oxidative damage in apoptotic cell death. We suggest that 
mitochondrial oxidative damage plays an important role in ROS-induced apoptosis. Further work using these and other 
mitochondrially targeted compounds to dissect out the role of  mitochondrial oxidative changes in peroxide-induced apop-
tosis is ongoing. 
The findings reported demonstrate that mitochondrially targeted antioxidants such as mito vit E + N-acetylcarnosine in 
the eye drop formulation with carboxymethylcellulose can be used to investigate the role of  mitochondrial oxidative stress 
in retinal neuronal cells (RGCs) death and may represent a new pharmacologic tool to mitigate complex ocular pathology 
for the treatment of  sight-threatening eye diseases and, especially, neurodegeneration originating from an oxidative injury 
and glaucomatous neurodegeneration. This strategy also has potential for unraveling the contribution of  oxidative stress to 
other ocular pathologies involving mitochondrial dysfunction.
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Introduction
Loss of  vision is the second greatest, next to death, fear among 
the elderly. The eye is a unique organ because of  its constant ex-
posure to radiation, atmospheric oxygen, environmental chem-
icals and physical abrasion. The number of  people with visual 
impairment worldwide in 2002 was in excess of  161 million, of  
whom about 37 million were blind [1]. The burden of  visual im-
pairment is not distributed uniformly throughout the world: the 
least developed regions carry the largest share. Visual impairment 
is also unequally distributed across age groups, being largely con-
fined to adults 50 years of  age and older. A distribution imbalance 
is also found with regard to gender throughout the world: females 
have a significantly higher risk of  having visual impairment than 
males. Notwithstanding the progress in surgical intervention that 
has been made in many countries over the last few decades, cata-
ract remains the leading cause of  visual impairment in all regions 
of  the world, except in the most developed countries. Other ma-
jor causes of  visual impairment are, in order of  importance, glau-
coma, age-related macular degeneration, diabetic retinopathy and 
trachoma [1]. 
Oxidation Reactions in Ocular Pathologies
Oxidation-reduction mechanisms have special importance in the 
eye. Oxidative damage can result in a number of  molecular chang-
es that contribute to the development of  glaucoma, cataract, and 
other eye diseases [2-4]. That oxidative stress mechanisms in oc-
ular tissues have been hypothesized to play a role in diseases such 
as glaucoma, cataract, uveitis, retrolental fibroplasias, age-related 
macular degeneration and various forms of  retinopathy provides 
an opportunity for new approaches to their prevention and treat-
ment [2]. There are numerous indications of  a crucial role of  re-
active oxygen species (ROS) in the main age-related ocular pathol-
ogies (Figure 1), i.e. retinopathies (maculodystrophy [5, 6], retinitis 
pigmentosa [7, 8], hereditary optic neuropathy [9]), as well as glau-
coma [10, 11], cataract [12-15], and autoimmune uveitis [16, 17]. 
Polyunsaturated fatty acids in mitochondrial cardiolipin are first 
of  all attacked by mitochondria-produced ROS that are quenched 
by mitochondria-targeted antioxidants [18]. This is why the 
above-listed pathologies attracted our attention as a possible field 
of  therapeutic application of  natural ophthalmic and synthetic 
mitochondria-targeted antioxidants.
Cataract formation, the opacification of  the eye lens, is one of  
the leading causes of  human blindness worldwide, accounting for 
47.8% of  all causes of  blindness [1]. 
Although great advances have been made in surgical treatment, 
the incidence of  cataracts in developing countries is so high that 
it overwhelms the capacity of  surgical programs.Cataract and 
age-related macular degeneration (AMD) are the major causes of  
vision impairment and blindness worldwide. Both conditions are 
strongly age related with earlier signs (usually asymptomatic) oc-
curring in middle age and becoming severer and more prevalent 
with increasing age. Primary open-angle glaucoma (POAG), the 
most common form of  glaucoma, is a slowly progressive atrophy 
of  the optic nerve, characterized by loss of  peripheral visual func-
tion and is usually associated with elevated intraocular pressure. 
Glaucoma is the second leading cause of  vision loss in the world. 
The number of  people with primary glaucoma is estimated at 
nearly 66.8 million by the year 2000, with 6.7 million of  them 
suffering from bilateral blindness [19]. The molecular basis of  
POAG is mostly unknown. Several theories of  its pathogenesis 
have been proposed, including mechanic and ischaemic ones (re-
viewed in ref. [19]). The aetiology of  these conditions is thought 
to fit with the 'free radical theory' of  ageing which postulates that 
ageing and age-related diseases result from the accumulation of  
cellular damage from ROS. Oxidation–reduction mechanisms 
have special importance in the eye. Oxidative damage can result 
in a number of  molecular changes that contribute to the develop-
ment of  glaucoma, cataract, and other eye diseases [3, 4]. If  the 
Figure 1. Topical administration is generally considered the preferred route for the administration of  ocular drugs due to its 
convenience and affordability. Drugs applied in this manner can be packaged in multiple forms, including solutions, oint-
ments, and suspensions. Corneal absorption is limited by drainage of  the instilled solutions, lacrimation, tear turnover, me-
tabolism, tear evaporation, non-productive absorption/adsorption, limited corneal area, poor corneal permeability, binding 
by the lacrimal proteins, enzymatic degradation, and the corneal epithelium itself. These limitations confine the absorption 
window to a few minutes after administration and reduce corneal absorption to < 5% [2-16].
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free radical theory of  aging is applied to the eye, an altered anti-
oxidant/oxidant balance should be evident for age-related ocular 
diseases, such as age-related macular degeneration, cataract, and 
glaucoma [20].
The studies investigating the relation between POAG, oxidant 
stress, and antioxidant systems were carried out at the tissue and 
cellular levels. ROS are generated as by-products of  cellular me-
tabolism, primarily in the mitochondria. Although ROS are essen-
tial participants in cell signaling and regulation, when their cellular 
production overwhelms the intrinsic antioxidant capacity, damage 
to cellular macromolecules such as DNA, proteins, and lipids en-
sues. Such a state of  "oxidative stress" is thought to contribute 
to the pathogenesis of  a number of  neurodegenerative diseases. 
Growing evidence supports the involvement of  oxidative stress 
as a common component of  glaucomatous neurodegeneration 
in different subcellular compartments of  retinal ganglion cells 
(RGCs) (Figure 2). Besides the evidence of  direct cytotoxic con-
sequences leading to RGC death, it also seems highly possible that 
ROS are involved in signaling RGC death by acting as a second 
messenger and/or modulating protein function by redox modifi-
cations of  downstream effectors through enzymatic oxidation of  
specific amino acid residues. Different studies provide cumulating 
evidence, which supports the association of  ROS with different 
aspects of  the neurodegenerative process. Oxidative protein mod-
ifications during glaucomatous neurodegeneration increase neu-
ronal susceptibility to damage and also lead to glial dysfunction. 
Oxidative stress-induced dysfunction of  glial cells may contribute 
to spreading neuronal damage by secondary degeneration. Oxida-
tive stress also promotes the accumulation of  advanced glycation 
end products in glaucomatous tissues. In addition, oxidative stress 
takes part in the activation of  immune response during glaucoma-
tous neurodegeneration, as ROS stimulate the antigen presenting 
ability of  glial cells and also function as co-stimulatory molecules 
during antigen presentation [11].
Mitochondrial energy production is a major source of  endog-
enous ROS. External sources of  ROS include environmental 
sources especially solar radiation, biomass fuels and tobacco 
smoking [21-24]. It is estimated that 0.2-2% of  oxygen taken up 
by cells is converted to ROS, through mitochondrial superoxide 
generation, by the mitochondria. Generation of  superoxide at 
complexes I and III has been shown to occur at both the matrix 
side of  the inner mitochondrial membrane and the cytosolic side 
of  the membrane (Figure 1C). While exogenous sources of  ROS 
such as UV light, visible light, ionizing radiation, chemotherapeu-
tics, and environmental toxins may contribute to the oxidative 
milieu, mitochondria are perhaps the most significant contribu-
tion to ROS production affecting the aging process. In addition to 
producing ROS, mitochondria are also a target for ROS which in 
turn reduces mitochondrial efficiency and leads to the generation 
of  more ROS in a vicious self-destructive cycle. Consequently, 
the mitochondria have evolved a number of  antioxidant and key 
repair systems to limit the damaging potential of  free oxygen rad-
icals and to repair damaged proteins [24].
Figure 2. Mitochondria-produced reactive oxygen species mediate a number of  mitochondria-dysfunction ocular patholo-
gies , i.e. retinopathies (maculodystrophy, retinitis pigmentosa , hereditary optic neuropathy), as well as glaucoma, cataract 
and autoimmune uveitis.
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Progressive thinning of  the photoreceptor outer nuclear lay-
er resulted from apoptotic cell death. These results support the 
hypothesis that oxidative damage to the RPE may play a role in 
some of  the key features of  AMD [19]. The resulting photooxida-
tive stress can cause acute or chronic retinal damage. The patho-
genesis of  age-related macular degeneration (AMD), involves ox-
idative stress and death of  the retinal pigment epithelium (RPE) 
followed by death of  the overlying photoreceptors (Figure 3). 
Evidence suggests that damage due to exposure to light plays a 
role in AMD and other age-related eye diseases. In the work to 
King et al., [20], a system for light-induced damage and death of  
the RPE, based on the human ARPE-19 cell line, was used. In-
duction of  mitochondria-derived reactive oxygen species (ROS) 
is shown to play a critical role in the death of  cells exposed to 
short-wavelength blue light (425 +/- 20 nm). ROS and cell death 
are blocked either by inhibiting the mitochondrial electron trans-
port chain or by mitochondria-specific antioxidants. These results 
show that mitochondria are an important source of  toxic oxygen 
radicals in blue light-exposed RPE cells and may indicate new ap-
proaches for treating AMD using mitochondria-targeted antioxi-
dants [20]. In terms of  AMD studies, steps in AMD pathogenesis 
that appear to be good targets for drug development include 1) 
oxidative damage; 2) lipofuscin accumulation (Figure 4); 3) chron-
ic inflammation; 4) mutations in the complement pathway; and 5) 
noncomplement mutations that influence chronic inflammation 
and/or oxidative damage (e.g., mitochondria and extracellular ma-
trix structure). Steps in neovascularization that can be targeted 
for drug development (Figure 5) and combination therapy include 
1) angiogenic factor production; 2) factor release; 3) binding of  
factors to extracellular receptors (and activation of  intracellular 
signaling after receptor binding); 4) endothelial cell activation (and 
basement membrane degradation); 5) endothelial cell prolifera-
tion; 6) directed endothelial cell migration; 7) extracellular matrix 
remodeling; 8) tube formation; and 9) vascular stabilization [25]. 
Defining the cell biology of  choroidal new vessel (CNV) forma-
tion and geographic atrophy will lead to identification of  different 
biochemical and cellular pathways that are the target of  AMD 
treatment. Many treatments and treatment combinations are un-
der study for AMD, but all work through a finite number of  met-
abolic pathways. Currently, the most effective proved therapy for 
AMD-associated CNVs is administered by repeated intravitreal 
injection of  agents that inhibit vascular endothelial growth fac-
tor, e.g., ranibizumab. Improved drug delivery will enhance pa-
tient satisfaction and possibly will enhance the effectiveness and 
reduce the risk of  current pharmacotherapy for AMD-associat-
ed CNVs. Combination therapy (e.g., verteporfin-photodynamic 
therapy + ranibizumab) appears to reduce the risk and enhance 
the effectiveness of  CNV treatment compared with monotherapy 
with currently available agents. Improved noninvasive diagnostic 
imaging may lead to better visual outcomes with existing thera-
peutic modalities. Improved imaging also may alter favorably the 
design of  future clinical trials for AMD-associated CNVs and 
thus reduce cost and increase the diversity of  sight-saving treat-
ments [26]. Areas of  investigation that will advance the field fur-
ther include combination therapy, improved drug delivery, and 
improved noninvasive, high-resolution diagnostic imaging. The 
logistics of  future clinical trials will be complicated by the need 
for an active treatment control group, more stringent definition 
of  successful treatment, and the increased numbers of  patients 
required for combination therapy studies [26].
Importantly, the aging eye appears to be at considerable risk from 
oxidative stress originated from the potential mitochondrial dys-
function at the certain stages of  ophthalmic disease progression 
and redox balance disturbance in age-related diseases. Mitochon-
dria are critical for ocular function as they represent the major 
source of  a cell's supply of  energy and play an important role in 
cell differentiation and survival. 
Figure 3. A. The retina is a highly organized, layered structure. The information begins at the receptors and flows through a 
second layer of  cells, called bipolar cells, and then continues through a third layer of  cells, called ganglion cells. In addi-
tion, at the level of  the receptor to bipolar connections, there are cells called horizontal cells that connect from receptors to 
other receptors. And at the level of  interconnections between the bipolar cells and the ganglion cells there are cells called 
amacrine cells that take as their input signals from bipolar cells and feed their output back onto other bipolar cells. From 
bottom to top there are: clear ganglion cell axons that make up the optic nerve, stained ganglion cell bodies, bipolar cells, 
photoreceptors, and the black layer of  pigment epithelium. B. Lipid peroxidation attack as a common component of  glau-
comatous neurodegeneration
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Mitochondrial dysfunction can occur as a result of  inherited mi-
tochondrial mutations (Figure 6) (e.g. Leber's hereditary optic 
neuropathy and chronic progressive external ophthalmoplegia) or 
stochastic oxidative damage which leads to cumulative mitochon-
drial damage and is an important factor in age-related disorders 
(e.g. age-related macular degeneration, cataract and diabetic reti-
nopathy). Mitochondrial DNA (mtDNA) instability is an import-
ant factor in mitochondrial impairment culminating in age-related 
changes and pathology, and in all regions of  the eye mtDNA 
damage is increased as a consequence of  aging and age-related 
disease. It is now apparent that the mitochondrial genome is a 
weak link in the defenses of  ocular cells since it is susceptible to 
oxidative damage and it lacks some of  the systems that protect 
the nuclear genome, such as nucleotide excision repair. Accumu-
lation of  mitochondrial mutations leads to cellular dysfunction 
and increased susceptibility to adverse events which contribute to 
Figure 4. Visual Cycle and enhanced oxidative stress in the retina involved in the mechanism of  age-related macular degen-
eration. Detection of  light destroys the visual pigment, necessitating its regeneration. The visual pigment, rhodopsin in the 
case of  rod photoreceptors, is composed of  a chromophore, 11-cis retinal, covalently linked to a protein, opsin . Absorption 
of  a photon isomerizes the chromophore to all-trans and results in the production of  an active intermediate that initiates 
the reactions leading to the change in the membrane potential of  the photoreceptor cell . The photoisomerization of  the 
chromophore also results in the destruction of  the visual pigment. The series of  reactions that remake the visual pigment 
comprise the visual cycle, and, in the case of  the rods, take place within the photoreceptor outer segment and the adjacent 
pigment epithelial cells. Within the rod outer segment, all-trans retinal is released from the photoactivated pigment and 
reduced to all-trans retinol by retinol dehydrogenase. All-trans retinol is then transported to the pigment epithelial cells, 
where it is refashioned into 11-cis retinal.
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Mitochondria are a primary site of  production of  free radicals. While more than 98% of  the molecular oxygen taken up by cells is 
fully utilized by cytochrome c oxidase to form water, this enzyme can release partly reduced species. Other enzymes of  the respiratory 
chain, and in particular complexes I and III, also produce partly reduced oxygen species including superoxide. These reactive oxygen 
species can react with nitric oxide to produce reactive nitrogen species including peroxynitrite. While a significant proportion of  the 
reactive oxygen and nitrogen species diffuse into the cytosol, a major portion remains in the mitochondrion.
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the pathogenesis of  numerous sporadic and chronic disorders in 
the eye [27]. 
Retinitis pigmentosa (RP) is a heterogeneous group of  diseases in 
which one of  a wide variety of  mutations selectively causes rod 
photoreceptor cell death (Figure 7). After rods die, cone photo-
receptors gradually die resulting in blindness. RP is a label for a 
group of  diseases caused by a large number of  mutations that re-
sult in rod photoreceptor cell death followed by gradual death of  
cones [7, 8]. The mechanism of  cone cell death is uncertain. Rods 
are a major source of  oxygen utilization in the retina and, after 
rods die, the level of  oxygen in the outer retina is increased. In 
the study to Komeima et al., [7], the scientists used the rd1 mouse 
model of  RP to test the hypothesis that cones die from oxidative 
Figure 5. Autofluorescence appearance at a fundus in a healthy eye. Studies have shown that the primary component of  
autofluorescence is lipofuscin. Lipofuscin (end product of  lipid peroxidation) appears to be a toxic by-product of  pho-
toreceptor shedding which accumulates in the lysosomal compartment of  the retinal pigment epithelial (RPE) cell. This 
by-product is constantly being cleared by the RPE and choriocapillaris, but through the body’s aging process and/or in 
association with various retinal diseases, clearing begins to slow down, leading to excessive build up. At critical concentra-
tions, the excess lipofuscin interferes with normal cell function leading to cell death.
Figure 6. WET type of  MACULAR DEGENERATION is a severe progression of  the dry type. As more and larger deposits 
of  drusen develop under the retina, larger areas of  the macula are damaged. Blood vessels growing up from below the reti-
na leak blood under the macula. These abnormal blood vessels may break and cause bleeding. Pressure from these pockets 
of  blood damage the light sensing cells, detroying the ability to see straight ahead. Scars often form, further destroying the 
sensitive macular area. Wet (also called “neovascular”) macular degeneration is the more unusual and more severe form of  
macular degeneration, capable of  causing sudden, rapid loss of  vision.
A: Neovascular, or wet, age-related macular degeneration; B: Fundus photo showing neovascular, or wet, age-related macu-
lar degeneration.
A B
Figure 7. Leber′s hereditary optic atrophy. A mitochondrial inherited bilateral condition, which appears suddenly in healthy 
people, primarily males, of  about the age of  20 and results in a marked loss of  vision and ultimately optic atrophy. A very 
small percentage of  people recover some visual acuity in one or both eyes after the disease has run its course.
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Figure 8. A. Retinitis Pigmentosa (RP) is a group of  eye disorders involving progressive degeneration of  the retina that 
leads to severe visual impairment. The age of  onset of  visuals symptoms is variable from early childhood to adulthood and 
is usually more severe if  the disorder is inherited as an autosomal trait. The disorder usually manifests with decline and 
loss of  night vision during adolescence, followed by loss of  peripheral vision in young adulthood, and loss of  central vision 
in later life due to the progressive loss of  rod and cone photoreceptors. Common symptoms include night blindness and a 
decreasing visual field, leading to tunnel vision, legal blindness or, in many cases, complete blindness. Clinical hallmarks 
are an abnormal fundus with bone-spicule deposits and attenuated retinal vessels. The electroretinogram findings in RP 
patients show reduced rod and cone response amplitudes. Mutations in the 7 genes analyzed in this panel have been re-
ported in approximately 31%-55% of  patients diagnosed with arRP/sporadic RP. Mutations in the CNGA1 gene have been 
reported in approximately 2%-4% of  patients diagnosed with arRP/sporadic RP.
B, C, D, E: Retinitis Pigmentosa is one of  the available therapeutic targets for the effective treatment during 4-6 months 
with the patented combined topical ophthalmic eye drop formulation including mitochondria-targeted antioxidants [27, 
104, 105]:
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(L-carnosine, mitochondria-targeted antioxidant) deeper in the eye tissues and fluids.
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Figure 9. Concept of  targeting mitochondria with functional agents [1-9] that use a vehicle to deliver an ROS scavenging 
payload into mitochondria. With the recognition of  the central role of  mitochondria in apoptosis, there is a need to develop 
specific tools to manipulate mitochondrial function within cells. Here we report on the development of  a novel antioxidant 
that selectively blocks mitochondrial oxidative damage, enabling the roles of  mitochondrial oxidative stress in different 
types of  cell death to be inferred. For details, see section 5 in the text.
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matrix cristae inner 
membrane
inter membrane 
space outer membrane
L-Carnosine (1) Natural mitochondria-targeted antioxidant.
A. The implemented N-acetylcarnosine ophthalmic prodrug lubricant eye drops.
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B. Untargeted lipophilic antioxidants.
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damage. Antioxidants reduce cone cell death in rd1/rd1 mice in-
dicating that cones die from oxidative damage in that model of  
rapidly progressive RP. A mixture of  antioxidants was selected to 
try to maximize protection against oxidative damage achievable by 
exogenous supplements; alpha-tocopherol (200 mg/kg), ascorbic 
acid (250 mg/kg), Mn(III) tetrakis (4-benzoic acid) porphyrin (10 
mg/kg), and alpha-lipoic acid (100 mg/kg) [7]. The data support 
the hypothesis that gradual cone cell death after rod cell death in 
RP is due to oxidative damage, and that antioxidant therapy may 
provide benefit [7]. The data suggest that oxidative damage con-
tributes to cone cell death regardless of  the disease causing muta-
tion that leads to the demise of  rods, and that in more slowly pro-
gressive rod degenerations, oxidative damage may also contribute 
to rod cell death. Protection from oxidative damage may be a 
broadly applicable treatment strategy in RP [7, 8]. Ghelli et al., [9] 
have tried to use different paradigms of  oxidative and metabolic 
stress in a cellular model of  Leber hereditary optic neuropathy 
(LHON), with the aim of  evaluating the efficacy of  potentially 
therapeutic molecules for the treatment of  this disease. Cybrids 
bearing one of  the three most common LHON pathogenic mu-
tations (11778/ND4, 3460/ND1, 14484/ND6) were incubated 
with two compounds known to induce oxidative injury, tert-butyl 
hydroperoxide (t-BH) and rotenone. To mimic metabolic stress, 
cells were incubated in a glucose-free medium containing ga-
lactose. Cell viability was determined using the MTT assay. To 
identify the apoptotic type of  cell death, nuclear morphology was 
examined after cell loading with Hoechst. Cellular glutathione 
(GSH), and oxidized glutathione (GSSG) levels were measured 
enzymatically. Incubation with t-BH caused apoptotic cell death 
of  control and LHON cybrids, whereas only LHON cybrids were 
damaged by rotenone concentrations up to 2.5 muM. Both types 
of  stress caused a marked imbalance in the glutathione levels, but 
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A. Natural mitochondria-targeted antioxidant L-carnosine (1), the implemented N-acetylcarnosine ophthalmic prodrug lubricant eye 
drops. 
B. Untargeted lipophilic antioxidants
C. Results suggest that mitochondria-targeted antioxidants are more effective inhibitors of  mitochondrial damage and apoptosis than 
the corresponding “untargeted” counterparts (i.e. Vit-E). (2-9): Structures of  mitochondria-targeted antioxidants are presented . 
(Clarification of  Structures 3,4) due to the large mitochondrial membrane potential, the cation was accumulated within mitochondria 
inside cells, where the ubiquinone moiety inserted into the lipid bilayer and was reduced by the respiratory chain. The ubiquinol deriva-
tive thus formed was an effective antioxidant that prevented lipid peroxidation and protected mitochondria from oxidative damage. 
After detoxifying a reactive oxygen species, the ubiquinol moiety was regenerated by the respiratory chain enabling its antioxidant 
activity to be recycled.
Selectively manipulating mitochondrial antioxidant status with targeted and recyclable antioxidants is a feasible approach to investigate 
the role of  mitochondrial oxidative damage in apoptotic cell death [27, 85, 86].
Figure 10. N-acetylcarnosine as the ophthalmic prodrug of  the natural mitochondria-targeted antioxidant L-carnosine in 
the topical ophthalmic application.
A B
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an increase in the GSSG/GSH + GSSG ratio was detected only 
after rotenone treatment. The efficacy of  several antioxidant and 
antiapoptotic compounds was then assessed in cells exposed to 
these two oxidative paradigms. Only exogenous GSH remarkably 
protected the t-BH- and rotenone-treated cybrids from cell death. 
In contrast, GSH was unable to increase the viability of  cybrids 
exposed to metabolic stress. The results suggest that GSH is an 
effective antioxidant compound to be tested as a potential treat-
ment for LHON [9]. The era of  mitochondria metabolic path-
way-based therapy for the early , advanced and late stages of  cata-
ract, primary open angle glaucoma (POAG) and AMD has begun 
[12].
At each step of  the disease development in the free radical oxi-
dation pathway, a new therapeutic treatment could be developed, 
including topical therapy with patented eye drop formulations but 
complete inhibition of  disease progression will likely require a 
combination of  the various treatments and creation of  the spe-
cific codrug formulations (Figures 7, 8) [12]. Combination ther-
apy will likely supplant monotherapy as the treatment of  choice 
because the clinical benefits (visual acuity and the specific clinical 
outcome of  treatment) will likely be superior to monotherapy 
in preventing the early, advanced or even late-stage of  cataracts, 
POAG, AMD and prevention of  complications thereof.
Fundamental Role of  Mitochondria in Ocular 
Tissue Metabolism and Ocular Disease Onset 
(Cataract, Retinal Disease and Glaucoma Onset)
Mitochondria provide energy generated by oxidative phosphor-
ylation and at the same time play a central role in apoptosis and 
aging. As a byproduct of  respiration, the electron transport chain 
is known to be the major intracellular site for the generation of  
ROS [28].
Tissues with high energy demands such as muscles, heart, liver, 
endocrine glands, brain and retina, have higher numbers of  mi-
tochondria per cell. Distribution of  mitochondria in the lens is 
associated with its development. The lens is composed of  cells 
that differentiate from an anterior layer of  cuboidal epithelia and 
migrate posteriorly to form elongated lens fiber cells that make 
up the lens nucleus [22]. During this process fiber cells synthesize 
high levels of  lens crystallins before losing their nuclei and mito-
chondria. Thus, the single monolayer of  epithelial cells that lines 
the anterior of  the lens, are the only lens cells that carry out aer-
obic metabolism and contain mitochondria aside from newly dif-
ferentiated fiber cells. The lens is especially susceptible to damage 
with aging since lens the cells and their cellular proteins are not 
turned over or replaced in this encapsulated tissue. The proteins 
at the center of  the eye are some of  the oldest in the body and 
obviously susceptible to age related oxidative damage. Damage to 
the mitochondria of  the epithelial cells may result in ROS pro-
duction that is thought to affect the proteins of  the underlying 
fiber cells.
Oxidative stress has long been recognized as an important medi-
ator of  apoptosis in lens epithelial cells and also plays an import-
ant role in the pathogenesis of  cataracts [29-33]. The lens exists 
in an environment that is rich in endogenous sources of  ROS, 
which are produced by the high local oxygen concentration, the 
chronic exposure to light, and the pathogenic activities of  lens 
epithelial cells [34]. Although multiple physiologic defenses exist 
to protect the lens from the toxic effects of  light and oxidative 
damage, mounting evidence suggests that chronic exposure to 
oxidative stress over the long-term may damage the lens and pre-
dispose it to cataract development. After exposure to oxidative 
stress, the redox set point of  the single layer of  the lens epithelial 
cells (but not the remainder of  the lens) quickly changes, going 
from a strongly reducing to an oxidizing environment. Almost 
concurrent with this change is extensive damage to DNA and 
membrane pump systems, followed by loss of  epithelial cell via-
bility and death by necrotic and apoptotic mechanisms. The data 
suggest that the epithelial cell layer is the initial site of  attack by 
oxidative stress and that involvement of  the lens fibers follows, 
leading to cortical cataract [32]. Lipid compositional changes in 
lens epithelial cells (HLE B-3) grown in a hyperoxic atmosphere 
were studied to determine if  oxidation could cause changes in the 
amount and type of  phospholipid similar to those found in vivo 
with age and cataract. The phosphatidylcholines in HLE B-3 cells 
were 8 times more unsaturated than the sphingomyelins. Cell via-
bility was the same for cells grown for up to 48 h in a normoxic or 
hyperoxic atmosphere. Lipid peroxidation (LPO) was about three 
times higher after growth in a hyperoxic atmosphere compared 
with cells grown in a normoxic atmosphere. The lack of  change in 
the relative amount of  sphingomyelin and the decrease in phos-
phatidylcholine coupled with the increase in lysophosphatidylcho-
line support the idea that similar mechanisms may be responsible 
for the lipid compositional changes in both lens epithelial and 
fiber cells. It is postulated that lipases eliminate oxidized unsatu-
rated glycerolipids, leaving a membrane increasingly composed of  
more ordered and more saturated sphingolipids. Oxidative stress 
leads to changes in membrane composition that are consistent 
with those seen with age in human epithelial cells [34]. Loss of  
protein sulfhydryl groups, and the oxidation of  methionine resi-
dues, are progressive and increase as the cataract worsens until > 
90% of  cysteine and half  the methionine residues are oxidised in 
the most advanced form. By contrast, there may be no significant 
oxidation of  proteins in the centre of  the lens with advancing age, 
even past age 80. The key factor in preventing oxidation seems to 
be the concentration of  nuclear glutathione (GSH) [33].
Apoptosis is a physiologic process of  cell death that plays a critical 
role in a variety of  biologic systems, which has been identified as 
providing an important molecular basis for both the initiation and 
progression of  cataracts [35-37]. There are distinct mechanisms 
that execute apoptosis according to various different apoptotic 
stimuli, and these are classified into the mitochondria-dependent 
pathway (intrinsic pathway) and the death receptor-dependent 
pathway (extrinsic pathway). Previous studies have demonstrated 
the capacity of  antioxidant protection of  the mitochondria-de-
pendent pathway associated with lens opacification in cultured 
lenses [38-41]. Mitochondrial damage results in the release of  cy-
tochrome c from the impaired mitochondria into the cytoplasm, 
which contributes to programmed cell death [42]. In the rat lenses 
mitochondrial loss in superficial cortical fibre cells may originate 
at the sutures and may compensate for loss of  optical quality at 
the sutures [41].
The lens epithelial cells differentiate into lens fiber cells through 
a process, which utilizes the same regulators as those in apoptosis 
at multiple signaling steps. Both in vitro and in vivo studies have 
shown that treatment of  adult lens with stress factors induces 
apoptosis of  lens epithelial cells, which is followed by catarac-
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togenesis [35]. It is well established that various factors such as 
oxidative stress, UV, and other toxic agents can induce both in 
vivo and in vitro cataract formation. However, a common cellu-
lar basis for this induction has not been previously recognized. 
The published study of  lens epithelial cell viability suggests such 
a general mechanism [37]. When lens epithelial cells from a group 
of  20 cataract patients 12 to 94 years old were analyzed by ter-
minal deoxynucleotidyl transferase (TdT) labeling and DNA 
fragmentation assays, it was found that all of  these patients had 
apoptotic epithelial cells ranging from 4.4 to 41.8%. By contrast, 
in eight normal human lenses of  comparable age, very few apop-
totic epithelial cells were observed. Li et al., [37] suggest that cat-
aract patients may have deficient defense systems against factors 
such as oxidative stress and UV at the onset of  the disease. Such 
stress can trigger lens epithelial cell apoptosis that then may initi-
ate cataract development. To test this hypothesis, it has been also 
demonstrated that hydrogen peroxide at concentrations previous-
ly found in some cataract patients induces both lens epithelial cell 
apoptosis and cortical opacity [37]. Moreover, the temporal and 
spatial distribution of  induced apoptotic lens epithelial cells pre-
cedes development of  lens opacification. These results suggest 
that lens epithelial cell apoptosis may be a common cellular basis 
for initiation of  noncongenital cataract formation [37]. Trans-
forming growth factor beta(2) (TGF-beta(2)), a growth regulator 
of  human lens epithelial cells (HLECs), also regulates the death 
of  lens epithelial cells. Dose-response analysis showed that the 
TGF-beta(2) concentration needed to induce HLECs death (100 
pg/ml) was 10 times that needed to inhibit growth in these cells 
(10 pg/ml) [36]. TGF-beta(2)-induced apoptosis in HLECs was 
preceded by an induction of  ROS and a decrease in glutathione in 
the intracellular content, indicating that this factor induces oxida-
tive stress in HLECs. Studies performed to analyze the levels of  
c-fos mRNA, a gene whose expression is modulated by the redox 
state, demonstrated that only high, apoptotic concentrations of  
TGF-beta(2) (100 pg/ml) produced an increase in the mRNA lev-
els of  this gene, the level of  induction being similar to that found 
when cells were incubated in the presence of  hydrogen peroxide 
[36]. Finally, the cell death induced by TGF-beta(2) in HLECs was 
partially blocked by radical scavengers, which decreased the per-
centage of  apoptotic cells, whereas these agents did not modify 
the growth-inhibitory effect elicited by TGF-beta(2) in these cells. 
The results presented in this published study provide evidence for 
the involvement of  an oxidative process in the apoptosis elicited 
by TGF-beta(2) in HLECs [36]. The effect of  R, S, and racemic 
forms of  α-lipoic acid was tested on the formation of  opacity in 
normal rat lenses incubated with 55.6 mM glucose, as a model for 
in vivo diabetic cataractogenesis [40]. Control lenses, incubated 8 
days with 5.56 mM glucose, did not develop opacities. Formation 
of  lens opacities in vitro was correlated with lactate dehydrogenase 
(LDH) leakage into the incubation medium. Opacity formation 
and LDH leakage, resulting from incubation in medium contain-
ing 55.6 mM glucose to model diabetes, were both suppressed by 
the addition of  1 mM R-lipoic acid. Addition of  1 mM racemic 
lipoic acid reduces these damaging effects to the lens by one-half, 
while S-lipoic acid potentiated LDH leakage, consistent with the 
hypothesis that R-lipoic acid is the active form. Although HPLC 
analysis demonstrated that both stereoisomers of  lipoic acid were 
reduced to dihydrolipoate at comparable rates by the intact lens, 
the mitochondrial lipoamide dehydrogenase system is highly spe-
cific for reduction of  exogenous R-lipoic to dihydrolipoic acid. 
Stereospecific protection against this opacity is consistent with 
specific reduction of  R-lipoic acid in mitochondria of  the vulner-
able cells at the lens equator where the first globular degeneration 
is seen in glucose cataract [40].
Exposure to solar and occupational ultraviolet (UV) radiation, 
and thus production of  ROS and subsequent cell death, has been 
implicated in a large spectrum of  skin and ocular pathologies, in-
cluding cataract. Retinal pigment epithelial cell apoptosis gener-
ates photoreceptor dysfunction and ultimately visual impairment. 
Normal morphological change is presumably allowing energy 
transmission across the cell from regions of  low to regions of  
high ATP demand. Lack of  mitochondrial movement, fragmenta-
tion, and swelling of  mitochondria may represent early morpho-
logical changes following oxidative stress that may lead to activa-
tion of  caspase-mediated apoptotic pathways [28].
The retina is the most oxygen consuming tissue in the body with 
consumption level around 50% higher than the brain or kidneys 
[43]. The central retina mediates high acuity vision, and its pro-
gressive dysfunction due to macular degeneration is the leading 
cause of  visual disability among adults in industrialized societies 
[43]. The macula is a source of  high metabolic activity, and is 
therefore exposed to correspondingly high levels of  ROS. With 
age, the balance between production of  ROS and local antiox-
idant levels is shifted, and damage ensues. Systemic ROS and 
antioxidant levels in AMD reflect these local processes [44]. In 
the retina, mitochondria are found throughout but the highest 
number of  mitochondria per cell is found in the photoreceptors. 
The retina captures and converts light between 400-760 nm into 
electrical signals that are sent to the brain by way of  the optic 
nerve and in the process helps to translate these electrical signals 
into what is known as vision. The same light that allows vision 
to occur is nevertheless also potentially toxic to retinal cells in 
certain situations. The shorter wavelengths of  light are known to 
interact with chromophores in photoreceptors and pigment epi-
thelial cells to cause oxidative stress and severe damage. Indeed 
it is generally accepted that short wavelength light effects is one 
cause for loss of  photoreceptor function in age-related macular 
degeneration. Recent studies have demonstrated that light may 
be a contributing factor for the death of  retinal ganglion cells 
in certain situations. Light as impinging on the retina, especially 
the short wavelength form, affect mitochondrial chromophores 
and can result in neurone death. Importantly ganglion cell axons 
within the eye are laden with mitochondria and unlike the outer 
retina are not protected from short wavelength light by macu-
lar pigments. It has therefore been proposed that when ganglion 
cell function is already compromised, as in glaucoma, then light 
impinging on their mitochondria might be a contributor to their 
eventual demise [45]. 
Mitochondria are central to retinal cell function and survival. 
There is increasing evidence to support an association between 
mitochondrial dysfunction and a number of  retinal pathologies 
including age-related macular degeneration (AMD), diabetic reti-
nopathy and glaucoma. The past decade has highlighted mitochon-
drial genomic instability as an important factor in mitochondrial 
impairment culminating in age-related changes and age-related 
pathology. This represents a combination of  the susceptibility of  
mitochondrial DNA (mtDNA) to oxidative damage and a limited 
base excision repair pathway. This random cumulative mtDNA 
damage leads to cellular heteroplasmy and, if  the damage affects 
a sufficient proportion of  mitochondria within a given cell, re-
sults in loss of  cell function and greater susceptibility to stress. 
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mtDNA damage is increased in the neural retina and RPE with 
ageing and appears to be greatest in AMD. It thus appears that the 
mitochondrial genome is a weak link in the antioxidant defenses 
of  retinal cells and that deficits in mitochondrial DNA (mtDNA) 
repair pathways are important contributors to the pathogenesis 
of  retinal degeneration [46].
Specifically targeting mitochondria with pharmacological agents 
able to protect against oxidative stress or promote repair of  mtD-
NA damage may offer potential alternatives for the treatment of  
retinal degenerations such as AMD [46].
ROS Production in Mitochondria
Mitochondria are sometimes referred to as the powerhouses of  
the cell since they generate most of  the cells chemical energy re-
quirement in the form of  adenosine triphosphate (ATP). They 
also have a significant role in regulating apoptosis and necrosis, 
ROS levels, cellular signaling, control of  the cell cycle, and growth 
and differentiation [47]. The new awareness has sparked a new 
and growing area of  mitochondrial research, that has become of  
great interest to a wide variety of  scientists ranging from those 
involved in elucidating the role of  mitochondria in cell death and 
aging to those interested in either suppressing or facilitating these 
processes as it relates to identifying new therapies or drugs for 
human disease [47]. Mitochondria are also involved in calcium up-
take and release, production of  NADH, synthesis of  DNA, RNA 
and proteins, DNA repair and metabolic pathways.
Mitochondria are a double membrane organelle with four distinct 
compartments, the outer membrane, inner membrane, intermem-
brane space and the matrix. It is the only organelle apart from the 
nucleus to contain its own DNA, mtDNA is a circular molecule 
of  just over 16000 base pairs making up 37 genes that encode 
13 components of  the electron transport chain, and transcription 
and translational machinery [22]. Oxidation of  fuels, such as glu-
cose, generates reducing equivalents that feed into the electron 
transport chain of  the mitochondria [48]. The electron transport 
chain generates ATP by oxidative phosphorylation, creating a 
proton gradient through sequential transfer of  electrons donat-
ed by reducing equivalents. This complex system is made up of  
five multi enzyme subunits, NADH dehydrogenase comprises 
complex I (46 subunits), succinate dehydrogenase is complex II 
(4 subunits), cytochrome C reductase and cytochrome C oxidase 
make up complexes III and IV respectively (11 and 13 subunits). 
Complex V is the ATP synthase (16 subunits) that uses the proton 
gradient created by the first four complexes to drive phosphory-
lation of  ADP to form the energy rich ATP. A great deal of  re-
search indicates that dysfunctional mitochondria are the primary 
site of  ROS [49]. In addition to the well-established role of  the 
mitochondria in energy metabolism, regulation of  cell death has 
recently emerged as a second major function of  these organelles. 
This, in turn, seems to be intimately linked to their role as the 
major intracellular source of  ROS which are mainly, generated at 
Complex I and III of  the respiratory chain. Excessive ROS pro-
duction can lead to oxidation of  macromolecules and has been 
implicated in mtDNA mutations, ageing, and cell death. Although 
mitochondrial dysfunction can cause ATP depletion and necrosis, 
these organelles are also involved in the regulation of  apoptotic 
cell death by mechanisms, which have been conserved through 
evolution. The essential role of  mitochondrial oxidative phos-
phorylation in cellular energy production, the generation of  reac-
tive oxygen species, and the initiation of  apoptosis has suggested 
a number of  novel mechanisms for mitochondrial pathology [50]. 
Increasingly, mitochondria are thought to play a regulatory role in 
cell death partly due to its role as a source of  ROS and due to the 
release of  cytochrome C and other pro-apoptotic factors that acti-
vate caspases and trigger apoptosis [22]. Cytochrome c release oc-
curs by a two-step process that is initiated by the dissociation of  
the hemoprotein from its binding to cardiolipin, which anchors it 
to the inner mitochondrial membrane. Oxidation of  cardiolipin 
reduces cytochrome c binding and results in an increased level 
of  "free" cytochrome c in the intermembrane space. Conversely, 
mitochondrial antioxidant enzymes protect from apoptosis [51].
Cytochrome C is a small globular heme containing electron carri-
er in the electron transport chain of  the mitochondria. Its prima-
ry role in the electron transport chain is a crucial one, shuttling 
electrons from Complex III (ubiquinol: cytochrome c reductase) 
to complex IV (cytochrome oxidase), however, its release from 
the mitochondria to the cytosol is the initiating factor for the in-
ternal apoptotic pathway. The release of  cytochrome C is a two 
step process, initiated by release of  the hemoprotein from its 
binding to cardiolipin at the inner mitochondrial membrane [51]; 
this results in a pool of  free cytochrome C in the intermembrane 
space. Subsequent permeabilization of  the outer mitochondrial 
membrane releases cytochrome C into the cytosol where it binds 
apoptotic peptidase activating factor 1 (APAF1) [22]. Many lethal 
agents target the mitochondria and cause release of  cytochrome c 
and other pro-apoptotic proteins, which can trigger caspase acti-
vation and apoptosis [49]. Conversely, mitochondrial antioxidant 
enzymes protect from apoptosis [51].
Mitochondria are a cell's single greatest source of  ROS. ROS are 
important for many life sustaining processes of  cells and tissues, 
but they can also induce cell damage and death. If  their produc-
tion and levels within cells is not effectively controlled, then the 
detrimental effects of  oxidative stress can accumulate. Oxidative 
stress is widely thought to underpin many ageing processes, and 
the oxidative stress theory of  ageing is one of  the most widely ac-
knowledged theories of  ageing. As well as being the major source 
of  ROS, mitochondria are also a major site of  oxidative damage 
[48]. More than 95% of  O2ˉ•, produced during normal metabo-
lism is generated by the electron transport chain in the inner mi-
tochondrial membrane. Correspondingly, mitochondria are also 
the major target of  ROS [49]. Such damage to the mitochondrial 
DNA may contribute to the age-associated decline in mitochon-
drial function. Mitochondrial DNA may be more susceptible to 
oxidative damage than to nuclear DNA [52] because of  its prox-
imity to electron transport chains, lack of  protective histones, and 
insufficient repair mechanisms [53]. Furthermore, mitochondrial 
DNA encodes several subunits of  different respiratory complex-
es [50]. ROS-induced DNA damage may lead to the production 
of  more ROS, thus perpetuating a vicious cycle.
Hence, there is accumulating evidence supporting a direct link 
between mitochondria, oxidative stress and cell death.
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The Mitochondria-Targeted Drugs including Mi-
toquinone (Mito-Q) and Mitovitamin E (Mito-
Vit-E) are a New Class of  Antioxidants containing 
the Triphenylphosphonium Cation Moiety that 
Facilitates Drug Accumulation in Mitochondria
Enhanced mitochondrial oxidative damage is a prominent feature 
of  most age-related human diseases including human cataract and 
neurodegenerative eye disorders, such as age-related macular de-
generation and glaucomatous neuropathy. Aberrant electron leak-
age from mitochondria in the respiratory chain in oxidant-stressed 
cells triggers the formation of  ROS [54], leading to enhanced oxi-
dative damage in mitochondria [54]. The increased oxidative dam-
age in mitochondria induces the mitochondrial permeability tran-
sition resulting in apoptotic or necrotic cell death [55]. Oxidants 
generated by mitochondria appear to be the major source of  the 
oxidative lesions that accumulate with age. Several mitochondrial 
functions decline with age. The contributing factors include the 
intrinsic rate of  proton leakage across the inner mitochondrial 
membrane (a correlate of  oxidant formation), decreased mem-
brane fluidity, and decreased levels and function of  cardiolipin, 
which supports the function of  many of  the proteins of  the in-
ner mitochondrial membrane. Age-associated accumulation of  
mitochondrial deficits due to oxidative damage is likely to be a 
major contributor to cellular, tissue, and organismal aging [55]. 
Mitochondria play a major role in regulating apoptosis through 
enhanced release of  cytochrome c that results in the activation of  
caspases and subsequent cell death [56, 57]. Alterations in mi-
tochondrial membrane structure and function can occur in a 
caspase-independent fashion and have a higher predictive value 
for cell death than caspase activation. Douglas Green and Guido 
Kroemer argue that caspases might have a dual function in the 
apoptotic process: first, as signal-transduction molecules that act 
as facultative inducers of  mitochondrial membrane changes, and, 
second, as processing enzymes that orchestrate the apoptotic phe-
notype. They propose a model for initiation of  apoptosis in which 
mitochondria and caspases engage in a self-amplifying pathway of  
mutual activation [56]. 
The essential role of  mitochondrial oxidative phosphorylation 
in cellular energy production, the generation of  ROS, and the 
initiation of  apoptosis has suggested a number of  novel mech-
anisms for mitochondrial pathology in ophthalmic diseases [12, 
22]. Glaucoma is increasingly recognized as a neurodegenerative 
disorder, characterized by the accelerated loss of  retinal ganglion 
cells (RGCs) and their axons. Open angle glaucoma prevalence 
and incidence increase exponentially with increasing age, yet the 
pathophysiology underlying increasing age as a risk factor for 
glaucoma is not well understood. Accumulating evidence points 
to age-related mitochondrial dysfunction playing a key role in the 
etiology of  other neurodegenerative disorders including amyo-
trophic lateral sclerosis, Alzheimer and Parkinson disease. The 
2 major functions of  mitochondria are the generation of  ATP 
through oxidative phosphorylation and the regulation of  cell 
death by apoptosis. Kong et al., [58] have summarized the evi-
dence to support the hypothesis that age-associated mitochondri-
al dysfunction renders RGCs susceptible to glaucomatous injury 
by reducing the energy available for repair processes and predis-
posing RGCs to apoptosis. Eliciting the role of  mitochondria in 
glaucoma pathogenesis may uncover novel therapeutic targets for 
protecting the optic nerve and preventing vision loss in glaucoma 
[58]. Aging is the greatest risk factor for glaucoma, implying that 
intrinsic age-related changes to retinal ganglion cells, their sup-
porting tissue or both make retinal ganglion cells susceptible to 
injury. Changes to the ocular vasculature, connective tissue of  the 
optic nerve head and mitochondria, which have been documented 
with advancing age and shown to be exacerbated in glaucoma, 
may predispose to glaucomatous injury. When considering such 
age-related changes, it is difficult to separate pathological change 
from physiological change, and cause from consequence. The in-
sults that predispose aged retinal ganglion cells to injury are likely 
to be varied and multiple; therefore, it may be more relevant to 
identify and treat common mechanisms that predispose to reti-
nal ganglion cell failure and/or death. Chrysostomou et al., [59] 
have suggested that mitochondrial dysfunction, as either a cause 
or consequence of  injury, renders retinal ganglion cells sensitive 
to degeneration. Therapeutic approaches that target mitochondria 
and promote energy production may provide a general means of  
protecting aged retinal ganglion cells from degeneration, regard-
less of  the etiology [59].
Mitochondrial abnormality has been implicated in various models 
of  RGC degeneration. Munemasa et al., [60] investigated modula-
tion of  mitochondrial membrane permeability and apoptosis-in-
ducing factor (AIF) translocation in a rat experimental glaucoma 
model. A decrease in MitoTracker-labeled mitochondria around 
the lamina area of  the optic nerve was observed in the glaucoma-
tous eye. Immunoblot analysis for axonal motor proteins showed 
that a significant decrease in kinesin 1 and myosin Va levels in the 
glaucomatous optic nerve. A significant decrease in mitochondrial 
thioredoxin 2 (Trx2) level was observed in the optic nerve after 
intraocular pressure (IOP) elevation. Translocation of  AIF from 
the mitochondria to the axoplasm and nucleus was observed in the 
axon and cell body, respectively. Trx2 over-expression in the mito-
chondrial membrane of  RGC-5 cells inhibited AIF translocation, 
resulting in cytoprotective effect against neurotoxicity induced 
by TNF-α/buthionine sulfoximine treatment. In vivo transfection 
was performed with EGFP-Trx2 plasmid and electroporation. 
Over-expression of  Trx2 in the retina and optic nerve indicated 
the protective effect against high IOP induced axonal degenera-
tion. Thus, the decreased mitochondrial membrane potential and 
subsequent AIF translocation were involved in the glaucomatous 
neurodegeneration. Furthermore, modulation of  mitochondria 
through the inhibition of  AIF translocation may become a new 
treatment strategy for neurodegenerative disease, such as glauco-
ma [60]. Mitochondria are critical for ocular function as they rep-
resent the major source of  a cell's supply of  energy and play an 
important role in cell differentiation and survival [60].
Several systemic or neurological mitochondrial diseases, including 
amyotrophic lateral sclerosis, Parkinson’s, Alzheimer’s, and Hun-
tington’s diseases, are characterized by dysfunctional or defective 
respiratory chain components (e.g. complexes I and III) that ex-
acerbate ROS formation [50, 55, 58, 61-68]. In addition, levels 
of  mitochondrial iron increased under these pathological condi-
tions [63-67] . Glutathione (GSH) exhibits several functions in the 
brain chiefly acting as an antioxidant and a redox regulator. GSH 
depletion has been shown to affect mitochondrial function prob-
ably via selective inhibition of  mitochondrial complex I activity 
[63]. Replenishment of  normal glutathione levels within the brain 
may hold an important key to therapeutics [63, 64].
The selective mitigation of  oxidative damage in mitochondria is 
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therefore an effective therapeutic strategy in such age-related hu-
man disorders. However, a major limitation of  antioxidant thera-
py in the treatment of  mitochondrial diseases has been the inabil-
ity to enhance antioxidant levels in mitochondria [68]. Strategies 
to prevent mitochondrial damage or to manipulate mitochondrial 
function in clinically useful ways may provide new therapies for 
a range of  human ocular disorders. We have outlined why mito-
chondria are a potentially important target for drug delivery and 
herewith we discuss how to deliver bioactive molecules selectively 
to mitochondria within cells during the treatment of  ophthalmic 
disorders [12]. Recently, there was a breakthrough in mitochon-
drial targeting of  antioxidants [12, 69, 70]. Mitochondrial function 
can be manipulated selectively by targeting bioactive compounds 
to mitochondria in living cells [69, 70]. Lipophylic antioxidants 
were covalently coupled to a triphenylphosphonium cation, and 
these compounds were preferentially taken up by mitochondria 
(Figure 8) [12, 69, 70]. These agents initially accumulated in the 
cytoplasmic region of  cells because of  the negative plasma mem-
brane potential (30–60 mV) [12, 69-71]. The lipophilic cations 
easily permeate through the lipid bilayers and subsequently ac-
cumulate several hundred-fold within mitochondria because of  a 
large mitochondrial membrane potential (150–170 mV; negative 
inside). These compounds pass easily through all biologic mem-
branes, including the ocular–blood barrier, and thus reach those 
ocular tissues most affected by mitochondrial oxidative damage. 
Murphy and coworkers initiated the practical realization of  the 
theoretical concept of  mitochondria-targeted antioxidants [68. 
69, 72, 73]. They synthesized and tested just a few of  mitochon-
dria-targeted antioxidants conjugated to the lipophilic alkyltriph-
enylphosphonium cations. Mito-Q, a derivative of  ubiquinone, 
and MitoVit-E, a derivative of  Vit-E, are two promising antioxi-
dants (Figure 8) that are specifically targeted to mitochondria [12, 
69-75]. Mitochondrial ubiquinone is a respiratory chain compo-
nent buried within the lipid core of  the inner membrane where 
it accepts 2 electrons from complexes I or II forming the corre-
sponding reduction product i.e. ubiquinol) which then donates 
electrons to complex III [76]. The ubiquinone pool in vivo exists 
largely in the reduced ubiquinol form acting as an antioxidant 
and a mobile electron carrier. alpha-Tocopherol (vitamin E) is a 
lipophilic chain-breaking antioxidant which inhibits lipid peroxi-
dation in isolated mitochondrial membranes and protects mem-
branes from oxidative damage. The primary oxidation product of  
vitamin E is the tocopheroxyl radical. By using submitochondrial 
particle membranes, it was shown that NADH, succinate, and 
reduced cytochrome c-linked oxidation reduce the tocopheroxyl 
radical, preventing both accumulation of  the radical and vitamin 
E consumption. As the electron transport chain can reduce to-
copheroxyl radical it may have an important physiological role in 
recycling vitamin E [77].
Ubiquinol has been reported to function as an antioxidant by do-
nating a hydrogen atom from one of  its hydroxyl groups to a lipid 
peroxyl radical, thereby decreasing lipid peroxidation (LPO) with-
in the mitochondrial inner membrane [77-79]. The ubisemiqui-
none radical formed during this process disproportionates into 
ubiquinone and ubiquinol [80, 81]. The respiratory chain subse-
quently recycles ubiquinone back to ubiquinol, restoring its anti-
oxidant function. Vitamin E (Vit-E) (or α-tocopherol) is another 
antioxidant within the mitochondrial inner membrane, and the 
tocopheroxyl radical formed from one electron oxidation of  
Vit-E regenerates Vit-E by reacting with ubiquinol [75, 77, 80, 
82]. The objective of  the published study to Lass and Sohal [75] 
was to elucidate the anti-oxidative roles of  coenzyme Q (CoQ) 
and alpha-tocopherol in mitochondrial membranes by determin-
ing whether CoQ directly scavenges peroxyl- and alkoxyl-radicals 
or indirectly regenerates alpha-tocopherol during autooxidation 
of  mitochondrial membranes. A comparison of  the interaction 
between alpha-tocopherol and CoQ during autooxidation was 
made between bovine and rat heart mitochondria, which differ 
approximately 15-fold in their alpha-tocopherol content. Results 
of  this study indicate that during autooxidation of  mitochondria, 
alpha-tocopherol acts as the direct radical scavenger, whereas ubi-
quinol regenerates alpha-tocopherol [75].
Results suggest that mitochondria-targeted antioxidants are more 
effective inhibitors of  mitochondrial damage and apoptosis than 
the corresponding “untargeted” counterparts (i.e. Vit-E) (Figures 
8,9 ) [61].
In 2006, an attempt was undertaken in Skulachev’s group to re-
place the ubiquinone moiety in MitoQ by plastoquinone. As a 
result, a series of  mitochondria-targeted antioxidants named SkQ 
has been synthesized (Figure 8) [83, 84]. It was reported [85-87] 
that the reactivity of  the ‘‘tailless’’ plastoquinol analogs to the per-
oxyl radicals was higher than that of  natural ubiquinols. 
Oxidized phospholipids play an important role in execution of  
the mitochondrial stage of  apoptosis and clearance of  apoptotic 
cells. During the LPO reaction, lipid hydroperoxides are formed 
as primary products. Several lines of  evidence suggest that lipid 
hydroperoxides can trigger cell death in many cell types, which 
may be mediated by mitochondria dysfunction pathway. With 
extended hyperoxic insult, the oxidants overwhelm the antioxi-
dant defense system and eventually cell death ensues [88]. ROS 
generation correlated inversely with mitochondrial membrane po-
tential and the amount of  cardiolipin, factors likely to contribute 
to loss of  cell viability [88]. The critical role of  mitochondria in 
programmed cell death leads to the design of  mitochondriotropic 
agents as a strategy in regulating apoptosis. According to the new 
IVP mitochondrion concept, mitochondria do not exist stably as 
distinct, individual, autonomous organelles. Rather, mitochondria 
form a network within cells; their continous fusion and fission is 
a highly dynamic process, adapting to the role the mitochondrion 
actually has in the cell. Increasing results confirm the role of  mi-
tochondrial fission and fragmentation in most forms of  apopto-
sis, even as a cause. This suggests that fragmented mitochondria 
are in a „bad“ condition, under oxidative stress. To overcome this 
problem, we developed natural forms of  mitochondria-targeted 
antioxidants (Figure 8, Structure (1)), non-hydrolized carnosine 
associated with the ophthalmic carrier typified for topical use 
(N-acetylcarnosine lubricant eye drops) (major proposed ad-
ministration way), ocular injection (intra-vitreal, subconjunctival, 
parabulbar) or even oral administration (synergistic administra-
tion with chaperones and reduced glutathione synthesis booster) 
[89-92].
The Effects of  L-Carnosine on Mitochondria
The effect of  carnosine on self-organization of  mitochondrial 
assemblies was studied in rat liver homogenate of  quiescent and 
excited animals. It was shown in separate electron microscopy ex-
periments with serial slices that under our conditions of  prepara-
tion of  homogenate, blocks of  native mitochondrial-reticular net-
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work in the cell, assemblies of  mitochondria, are kept. Carnosine 
was shown to prevent dissociation of  assemblies during storage. 
Its effect is maximal for more dissociated assemblies from excited 
animals with decreased ability for self-organization. Prevention 
of  disassembly of  organelles by carnosine can serve as one of  
the mechanisms of  carnosine-induced diminishing of  muscle 
fatigue under prolonged work [93]. L-Carnosine prevented both 
12-O-tetradecanoylphorbol-13-acetate (TPA)-and H2O2-induced 
DNA fragmentation, the loss of  mitochondrial membrane po-
tentials and blocked the release of  cytochrome c into cytosol. 
Subsequently, the cleavages of  poly (ADP-ribose) polymerase 
were significantly reduced in L-carnosine-treated cells. However, 
western blotting analysis revealed that p53 protein level did not 
change for 12h after TPA- and H2O2-treatment. Therefore, these 
results suggested that L-carnosine, an antioxidant, protected both 
H2O2- and TPA-induced apoptosis through mitochondrial path-
ways [94]. Carnosine addition to mitochondria or its accumulation 
in mitochondria under hypoxia is associated with activation of  
alpha-ketoglutarate oxidation and its formation through transam-
ination [95].
Recently, phospholipid peroxidation products gained a reputation 
as key regulatory molecules and participants in oxidative signaling 
pathways. Oxidation of  two anionic phospholipids--cardiolipin 
(CL) in mitochondria and phosphatidylserine (PS) in extramito-
chondrial compartments--is important signaling event, particular-
ly during the execution of  programmed cell death and clearance 
of  apoptotic cells. Quantitative analysis of  CL and PS oxidation 
products is central to understanding their molecular mechanisms 
of  action [96, 97]. Furthermore, specific characteristics of  CL in 
mitochondria--its asymmetric transmembrane distribution and 
mechanisms of  collapse, the regulation of  its synthesis, remod-
eling, and fatty acid composition--are given significant consider-
ation [97, 98]. Cytochrome c (cyt c) acts as a CL-specific per-
oxidase very early in apoptosis. At this stage, the hostile events 
are still secluded within the mitochondria and do not reach the 
cytosolic targets. CL oxidation process is required for the release 
of  pro-apoptotic factors into the cytosol. Manipulation of  cyt c 
interactions with CL, inhibition of  peroxidase activity, and pre-
vention of  CL peroxidation are prime targets for the discovery 
of  anti-apoptotic drugs acting before the "point-of-no-return" in 
the fulfillment of  the cell death program. During apoptosis, a mi-
tochondria-specific phospholipid, cardiolipin (CL), interacts with 
cytochrome c (cyt c) to form a peroxidase complex that catalyzes 
CL oxidation; this process plays a pivotal role in the mitochon-
drial stage of  the execution of  the cell death program. Several 
works were focused on redox mechanisms and essential struc-
tural features of  cyt c's conversion into a CL-specific peroxidase 
that represent an interesting and may be still unique example of  
a functionally significant ligand change in hemoproteins [96, 97]. 
Recently, it was demonstrated that peroxidase cyt c/CL complex-
es can utilize free fatty acid hydroperoxides (FFA-OOH) at excep-
tionally high rates that are approximately 3 orders of  magnitude 
higher than for H2O2 [96]. Interaction of  cyt c with negatively 
charged lipid membranes induces considerable disruption of  the 
native compact structure of  the protein and induces intermediate 
conformations between the native and the fully unfolded states, 
called a “molten globule.” This state, an “alternative folding,” is 
defined as a compact conformation with a secondary structure 
comparable to that of  the native state and fluctuating tertiary con-
formation due to a high enhancement of  intramolecular motion 
[99-102]. Phosphorus-31 NMR has been used to investigate the 
interaction of  cytochrome c with bilayers of  the anionic lipids 
dioleoyl phosphatidylglycerol (DOPG), dioleoyl phosphatidylser-
ine (DOPS), and diacyl phosphatidylinositol (diacylPI). All 31P 
NMR spectra revealed the typical line shapes characteristics of  
phospholipids in liquid-crystalline bilayers. The effects on the 31P 
chemical shift anisotropy (CSA) for each system reflect particular 
modes of  phospholipid headgroup interaction with cytochrome c 
[99]. The observed destabilization of  protein structure mediat-
ed by acidic phospholipids (and possibly formation of  folding 
intermediates at the membrane surface) may represent a gener-
al property of  a larger class of  water-soluble proteins for which 
membrane binding is governed by electrostatic forces [101]. In 
solution, stability and unfolding of  cyt c were extensively stud-
ied using deuterium exchange [103] and other experimental tech-
niques [104, 105 reviewed in ref. 97]. Stabilities of  different re-
gions of  the protein were very dissimilar: five distinct domains 
of  cyt c (foldons) with nonequivalent stabilities were identified, 
which participate in cooperative folding–unfolding of  the protein 
in a stepwise sequential way [103]. These structural domains are 
folded around the heme of  cyt c, which is covalently attached to 
the polypeptide chain by residues Cys14 and Cys17.
Accordingly, the new concepts in drug discovery based on the de-
sign of  mitochondria-targeted inhibitors of  cyt c/CL peroxidase 
and CL peroxidation with antiapoptotic effects have appeared. 
Therefore, mitochondria-targeted disruptors and inhibitors of  cyt 
c/CL peroxidase complexes and suppression of  CL peroxidation 
represent new strategies in anti-apoptotic drug discovery [106].
We have originally discovered that both carnosine and carcinine 
(10-25 mM) are capable of  inhibiting the catalysis of  linoleic 
acid and phosphatidylcholine liposomal peroxidation (LPO) by 
the O2ˉ˙-dependent iron-ascorbate and lipid-peroxyl-radical-gen-
erating linoleic acid 13-monohydroperoxide (LOOH)-activated 
haemoglobin systems, as measured by thiobarbituric-acid-reac-
tive substance. Carcinine and carnosine are good scavengers of  
OH˙ radicals, as detected by iron-dependent radical damage to 
the sugar deoxyribose. This suggests that carnosine and carcinine 
are able to scavenge free radicals or donate hydrogen ions. The 
iodometric, conjugated diene and t.l.c. assessments of  lipid hy-
droperoxides (13-monohydroperoxide linoleic acid and phospha-
tidylcholine hydroperoxide) showed their efficient reduction and 
deactivation by carnosine and carcinine (10-25 mM) in the liber-
ated and bound-to-artificial-bilayer states. This suggests that the 
peroxidase activity exceeded that susceptible to direct reduction 
with glutathione peroxidase. Imidazole, solutions of  beta-alanine, 
or their mixtures with peptide moieties did not show antioxidant 
potential [107]. Due to the combination of  weak metal chelating 
(abolished by EDTA), OH˙ and lipid peroxyl radicals scavenging, 
reducing activities to liberated fatty acid and phospholipid hy-
droperoxides, carnosine and carcinine appear to be physiologi-
cal antioxidants able to efficiently protect the lipid phase of  bi-
ological membranes and aqueous environments and act as the 
anti-apoptotic natural drug compounds. Removal of  excessive 
mitochondrial ROS by electron scavengers and antioxidants is a 
promising therapeutic strategy to reduce the detrimental effects 
of  UV radiation and other cataractogenic factors exposure. Local 
mitochondrial interaction is mediated by superoxide (O2ˉ˙ ) dif-
fusion and the O2ˉ˙ -dependent activation of  an inner membrane 
anion channel (IMAC). In contrast to other mitochondria-target-
ed antioxidants studied by Mitchel and Skulachev’s Groups, it is 
important that L-carnosine can scavenge superoxide anion radical 
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released from mitochondria in the outdside compartments of  the 
cells. Even at low concentrations, dipeptide carnosine forms a 
charge-transfer complex (Car ... O2ˉ˙ , lambda max = 265 nm) 
with the superoxide radical which changes the reactivity of  O2ˉ˙. 
The absorbance band of  the complex was shifted towards lower 
energy as compared to superoxide radical lambda max = 255 nm). 
The interaction of  carnosine with OH-radicals proceeding at very 
high rate and resulting in the formation of  a stable product sug-
gested another type of  dipeptide activity [108].
The IVP patented concept includes the integrated lens and oc-
ular tissues mitochondrial targeting with triphenyl-phosphoni-
um (TPP)-conjugated hydrophobic compounds combined with 
L-carnosine ophthalmic prodrug N-acetylcarnosine (Figures 8, 9), 
represents a promising approach for the development of  novel 
eye and specifically, cataract universal antioxidant protectors [89, 
90]. N-acetylcarnosine eye-drops have been shown to have mea-
surable effects to prevent and partially reverse cataracts within 
only 3-6-month of  topical ocular use [92, 109]. However, it is 
recommended that for maximum efficacy, that administration be 
continued for a period not less than 3-5 months. In addition, the 
drops’ effectiveness is increased the sooner they are used after 
a cataract is detected. Also, considering that senile cataracts are 
an on-going aging disorder, N-acetylcarnosine may be required 
on a regular basis to help maintain the eye's natural anti-oxidant 
defenses. Other than senile cataract, N-acetylcarnosine may have 
other benefits. The unique N-acetylcarnosine formula with its 
added and synergistic lubricants, could also provide beneficial re-
sults with the following eye-disorders [92, 109]: 
• Presbyopia. 
• Open-angle primary glaucoma (in combination with be-
ta-blockers). 
• Corneal disorders. 
• Computer vision syndrome. 
• Eye strain. 
• Ocular inflammation. 
• Blurred vision. 
• Dry eye syndrome. 
• Retinal diseases. 
• Vitreous opacities and lesions. 
• Complications of  diabetes mellitus and other systemic dis-
eases. 
• Contact lens difficulties, particularly with soft contact lenses. 
(Not only do the lubricants in the Can-C N-acetylcarnosine 
eye-drop help to make wearing contact lenses more com-
fortable, but n-acetylcarnosine is also believed to reduce the 
build up of  lactic acid in the eye, thus enabling the lens to be 
left safely in the eye for longer). 
Mitochondria are usually either the primary source of  ROS [110] 
or mediators of  burst of  ROS formation in other cellular com-
partments (“ROS-induced ROS release” [12, 111]). This is why 
it is reasonable to combine the N-acetylcarnosine lubricant eye 
drops acting as the ophthalmic prodrug of  naturally targeted to 
mitochondria L-carnosine endowed with pluropotent types of  
antioxidant activities with mitochondria-targeted rechargeable an-
tioxidant (see a number of  compounds presented in Figure 8) as a 
medicine to treat ocular diseases [reviewed in ref. [12]].
Altered redox and cytokine patterns suggest inhibition of  expres-
sion/activity of  metabolizing and antioxidant enzymes in tissues 
subjected to the action of  oxidative stress. Metabolic parameters 
indicating accelerated LPO, increased nitric oxide production and 
glutathione depletion in combination with increased inflammatory 
cytokines should be considered in biological definition and diag-
nosis of  ocular disorders. We suggest that pharmacologic loading 
of  intact cells with lipophilic antioxidants may compromise the 
yield of  valuable proprietary antioxidant enzymatic activities, such 
as superoxide dismutase and glutathione reductase activities and 
have the pathogenic importance of  intracellular ROS in antioxi-
dant overload states deprivation, inflammation, and cellular injury. 
The excessive treatment with lipophilic xenobiotic compound can 
lead to decrease of  antioxidant enzyme activities, namely, super-
oxide dismutase (SOD), catalase (CAT), glutathione peroxidase 
(GPx) and glutathione reductase (GR) associated with a higher 
amount of  MDA level. Although ROS are essential participants 
in cell signaling and regulation, when their cellular production 
overwhelms the intrinsic antioxidant capacity, damage to cellular 
macromolecules such as DNA, proteins, and lipids ensues. Oxida-
tive stress contributes to the pathogenesis of  a number of  the oc-
ular neurodegenerative diseases that might be protected with the 
described here with therapeutic modality. The combined phar-
macological use of  N-acetylcarnosine eye drop prodrug-codrug 
formulation as an ocular promoter of  L-carnosine activated by a 
triphenylphosphonium cation coupled bioactive molecules deliv-
ered to mitochondria can prevent the impediment of  antioxidant 
enzymatic activities and can prevent the exacerbation of  ophthal-
mic sight threatening disease [12].
Attractive Targets and Therapeutic Strategies of  
Drug Delivery to Mitochondria in the Treatment 
of  Oxidative Injury During Glaucomatous Neuro-
degeneration
Although retinal ganglion cells (RGCs) exhibit unique character-
istics of  antioxidant defense mechanisms [112], survival of  axo-
tomized RGCs is critically sensitive to the oxidative redox state; 
and decreasing ROS generation promotes the survival of  RGCs 
after axotomy [113]. Retinal light exposure is a source of  oxidative 
stress, and retinal cells contain molecules that scavenge or inacti-
vate ROS. Yet, ROS also play a role in signal transduction, and 
some retinal cells (e.g., neurotrophin-dependent retinal ganglion 
cells, RGCs) may use ROS as part of  the signaling process for 
cell death. RGCs might therefore have specialized mechanisms 
for regulating ROS levels. The hypothesis that RGCs might regu-
late ROS differently from other retinal cells was tested by studying 
their differential response to oxidative stress in vitro [112]. Growing 
evidence also supports that the oxidative stress evident in glauco-
matous tissues is an important factor for the loss of  these neurons 
during glaucomatous neurodegeneration. Most of  the proposed 
pathogenic mechanisms of  glaucomatous neurodegeneration are 
well-known to include an oxidative component. Histopatholog-
ical studies of  glaucomatous human donor eyes [114, 115] and 
experimental studies using different animal models of  glaucoma 
have demonstrated that while optic nerve axons are progressively 
lost in glaucomatous eyes, RGCs die through apoptosis [11, 116-
118]. The results suggest that retinal ganglion cells of  the adult rat 
die through apoptosis when the IOP is markedly increased. This 
raises new possibilities in the treatment of  glaucomatous damage 
to the retina, by the potential interruptibility of  a program for 
neuronal death [116]. Multiple pathogenic mechanisms triggered 
by elevated IOP and/or tissue hypoxia have been associated with 
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optic nerve degeneration and RGC apoptosis in glaucoma. A 
number of  genetic susceptibility factors also support the multi-
factorial nature of  the disease [119, 120]. During glaucomatous 
neurodegeneration, ROS may be directly neurotoxic to RGCs, 
may contribute to secondary degeneration by inducing glial dys-
function, and may also function as signaling molecules by acting 
as a second messenger and/or by regulating redox modifications 
of  downstream effectors [11]. Exact molecular mechanisms and 
the real impact of  oxidative stress on the development and pro-
gression of  glaucomatous neurodegeneration need to be further 
elucidated. An improved understanding of  the cellular mecha-
nisms leading to oxidative injury in RGCs during glaucomatous 
neurodegeneration, and modulation of  pathways involved in 
mediating cellular responses to oxidative stress, may offer unique 
opportunities for neuroprotective interventions aimed at the ef-
fective treatment of  glaucoma, a leading cause of  blindness [11].
In this work we proposed the combined use of  mitochondria-tar-
geted antioxidant mito Vit E and N-acetylcarnosine, an ophthal-
mic prodrug of  L-carnosine in formulation of  eye drops includ-
ing the mucoadhesive compound carboxymethylcellulose to help 
elucidate the role of  mitochondrial oxidative damage in apoptotic 
cell death (Figures 8,9) [12, 89, 90]. We suggest that mitochondrial 
oxidative damage plays an important role in ROS-induced apop-
tosis. Further work using these and other mitochondrially targeted 
compounds to dissect out the role of  mitochondrial oxidative 
changes in peroxide-induced apoptosis is ongoing. The findings 
reported here demonstrate that mitochondrially targeted antiox-
idants such as mito vit E + N-acetylcarnosine in the eye drop 
formulation with carboxymethylcellulose can be used to investi-
gate the role of  mitochondrial oxidative stress in RGCs cell death. 
This strategy also has potential for unraveling the contribution of  
oxidative stress to other ocular pathologies involving mitochon-
drial dysfunction [12, 89, 90].
Conclusion
The mitochondrial respiratory chain is a major source of  super-
oxide and consequently generated related ROS and, therefore, 
mitochondria accumulate oxidative damage more rapidly than the 
rest of  the cell, contributing to mitochondrial dysfunction and 
cell death in ocular degenerative diseases and in aging [11, 12, 18, 
89, 90]. Mitochondria are also central to activating apoptosis and 
oxidative damage can lead to cell death, however, the significance 
of  mitochondrial oxidative damage for cell death is unclear [70, 
121, 122]. The consequences of  mitochondrial dysfunction (col-
lapse of  the mitochondrial inner transmembrane potential, un-
coupling of  the respiratory chain, hyperproduction of  superoxide 
anions, disruption of  mitochondrial biogenesis, outflow of  matrix 
calcium and glutathione, and release of  soluble intermembrane 
proteins) entails a bioenergetic catastrophe culminating in the 
disruption of  plasma membrane integrity (necrosis) and/or the 
activation of  specific apoptogenic proteases (caspases) by mito-
chondrial proteins that leak into the cytosol (cytochrome c, apop-
tosis-inducing factor) with secondary endonuclease activation 
(apoptosis). The relative rate of  these two processes (bioenergetic 
catastrophe versus protease and endonuclease activation) deter-
mines whether a cell will undergo primary necrosis or apoptosis. 
The acquisition of  the biochemical and ultrastructural features of  
apoptosis critically relies on the liberation of  apoptogenic prote-
ases or protease activators from mitochondria. The fact that mito-
chondrial events control cell death has major implications for the 
development of  cytoprotective and cytotoxic drugs [122]. One 
approach to this problem is to selectively target antioxidants to 
mitochondria [12, 68-73].
This should allow the relative importance of  mitochondrial and 
cytoplasmic oxidative stress for cell death to be distinguished, and 
also enable the contribution of  mitochondrial damage to ocular 
pathologies associated with aging, diabetes, and apoptosis of  ret-
inal neuronal cells (RGCs) to be investigated in cell and animal 
models.
With the recognition of  the central role of  mitochondria in apop-
tosis, there is a need to develop specific tools to manipulate mito-
chondrial function within cells in ocular disorders, such as glauco-
ma, human cataract and retinal disorders. Here we report on the 
development of  a novel antioxidant eye drop formulation N-ace-
tylcarnosine eye drop prodrug–codrug as an ocular promot-
er of  L-carnosine, a natural mitochondria-targeted antioxidant, 
activated by a triphenylphosphonium cation coupled bioactive 
molelcules delivered to mitochondria that selectively blocks mi-
tochondrial oxidative damage, enabling the roles of  mitochon-
drial oxidative stress in different types of  ocular cell death to be 
inferred (Figure 7).
Due to the large mitochondrial membrane potential, the cation 
was accumulated within mitochondria inside cells, where the lipo-
philic moiety of  mitochondria-targeted antioxidant inserted into 
the lipid bilayer and was reduced by the respiratory chain. Due to 
the combination of  weak metal chelating (abolished by EDTA), 
OH˙ and lipid peroxyl radicals scavenging, reducing activities to 
liberated fatty acid and phospholipid hydroperoxides, carnosine 
derived in the ocular tissues and fluids from the ophthalmic pro-
drug N-acetylcarnosine, appears to be a physiological universal 
antioxidant able to efficiently protect the lipid phase of  biological 
membranes and aqueous environments and act as the anti-apop-
totic natural drug compound . After detoxifying a reactive oxygen 
species, the lipophilic moiety of  mitochondria-targeted antioxi-
dant was regenerated by the respiratory chain enabling its anti-
oxidant activity to be recycled. We have shown that selectively 
manipulating mitochondrial antioxidant status with targeted di-
peptide and recyclable antioxidants is a feasible approach to in-
vestigate the role of  mitochondrial oxidative damage in apoptotic 
cell death in sight-threatening eye disorders. This approach will 
have further clinical applications in investigating mitochondrial 
dysfunction in a range of  experimental models.
We conclude that, based on the data presented in this study, the 
combined eye drop formulation including N-acetylcarnosine 
prodrug–codrug as an ocular promoter of  L-carnosine, a natural 
mitochondria-targeted antioxidant , activated by a triphenylphos-
phonium cation coupled bioactive molelcules delivered to mito-
chondria that selectively block mitochondrial oxidative damage, 
may represent new pharmacologic tool to mitigate complex ocu-
lar pathology for the treatment of  sight-threatening eye diseases 
and, especially, neurodegeneration originating from an oxidative 
injury and glaucomatous neurodegeneration.
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